Lecture 15 - HIV - Cures Flashcards Preview

BIOM30002 - M2M > Lecture 15 - HIV - Cures > Flashcards

Flashcards in Lecture 15 - HIV - Cures Deck (18):
1

What are the differences between cure and remission?
What is the model for each?
What is the likelihood of both?

1. Cure: 'infectious disease model'
• eradication of all HIV-infected cells
• 'sterilising cure'
• likely to be very difficult in HIV

2. Remission: 'cancer model'
• long term health in the absence of cART
• HIV still present at low levels
• 'functional cure'
• rare, but not impossible

2

What are some unique cases of cure of HIV?

Berlin patient
• Received a BM transplant (from a donor naturally resistant to HIV)
• cART treatment halted
• infection did not come back
• has been off cART for 7 years

Mississippi baby
• very early treatment (within 30 hours of delivery)
• baby has been off cART for 2 years
• very low levels of virus, but no infection

3

How do latent infected T cells arise?

What can they do?

Why is this a problem?

HIV infection of resting CD4+ T cells

At any point, the cell can re-activate and release virus
They can undergo homeostatic proliferation

HAART does not kill latently infected T cells

4

Which cells does HAART target?

Activated CD4+ T cells

Does not target latently infected T cells

5

What is the latent reservoir?

Many resting CD4+ T cells that are infected with HIV:

Predominantly:
• Central Memory T cells

Also:
• Thymic T cells
• Naïve T cells
• Effector T cells

HAART can not target these cells

6

Describe anatomical reservoirs of HIV
List some

Certain parts of the body are sequestered from the drugs and the immune system
• Brain
• Lymph nodes
• GIT
• Testis

HAART can not target the infected cells in these organs

7

What are the strategies for a HIV cure?

1. Activating latently infected cells
2. Make cells resistant to HIV
3. Eliminate residual virus replication
4. Enhance HIV-specific immunity

8

Describe activating latent infection

1. Agent activates the integrated virus
2. Transcription, translation of HIV genes
3. HIV proteins expressed on the surface of the cell, virion shedding
4. Infected cell may die

9

What are some agents of latent infection reactivation?

• HDACi (e.g. Vorinostat)
• Cytokines: IL-7
• Disulfiram

10

Describe the function of HDACi

(Histone deacetylase inhibitors)

'Turns genes on'; reactivates latently infected cells

1. HDACi deacetylates the histones of the HIV DNA
2. Expression of HIV genes

Cell may die

11

What is observed in most patients when cART is stopped?

Rapid rebound of HIV RNA in serum

12

List three barriers to cure of HIV infection

HIV persists despite HAART

1. Latently infected T cells
2. Residual viral replication
3. Anatomical reservoirs

13

What is residual replication?
How often is it observed?

Observed in 1/3rd of people with HIV infection

cART is not effective at blocking replication of HIV in some T cells

14

What is Vorinostat?
Describe its function

It is a Histone deacetylase inhibitor (HDACi)

Function:
• Acetylation of HIV genes integrated into host genome → genes turned ON
→ Activates latent HIV in vivo

Evidence:
Has been shown to greatly increase gag copies in patients (evidence of gene expression)

15

What is a challenge to reactivation of latently infected cells?

Latently infected cells are rare

16

Give an overview of some methods of making cells resistant to HIV

Gene therapy

1. Blockage of HIV protein action
• RNA interference

2. Expression of an anti-viral factor
• Mutant APOBEC 3G

3. Elimination of integrated HIV
• LTR

4. Removal of an essential host factor
• CCR5

17

Describe how CCR5 can be used to make cells resistant to HIV infection

Is this safe?
What is the efficacy?

1. Isolation of CD4+ T cells from an HIV+ individual on cART

2. Nucleases cleave parts of DNA; removal of the gene for CCR5

3. Cells re-infused into the patient

4. HIV can not bind to the co-receptor, and thus cannot gain access to the host cell

Safety
• Infusion of CCR5 modified cells is safe

Efficacy:
• The CCR5 modified cells survive once re-infused

18

How common are latently infected CD4+ T cells in patients receiving HAART?

60 per million CD4+ T cells

Thus, they are quite rare

This makes it difficult to get rid of the latently infected cells